These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25543225)

  • 1. [Homozygous familial hypercholesterolemia. First case in Spain treated with lomitapide, an inhibitor of the synthesis of lipoproteins with apolipoprotein B].
    Alonso R; Mata P; Alonso Y Gregorio M; de Andrés R
    Med Clin (Barc); 2015 Sep; 145(5):229-30. PubMed ID: 25543225
    [No Abstract]   [Full Text] [Related]  

  • 2. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 3. Lomitapide.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):179-81. PubMed ID: 25702706
    [No Abstract]   [Full Text] [Related]  

  • 4. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lomitapide.
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):347-52. PubMed ID: 21846156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia.
    Blom DJ; Averna MR; Meagher EA; du Toit Theron H; Sirtori CR; Hegele RA; Shah PK; Gaudet D; Stefanutti C; Vigna GB; Larrey D; Bloedon LT; Foulds P; Rader DJ; Cuchel M
    Circulation; 2017 Jul; 136(3):332-335. PubMed ID: 28716835
    [No Abstract]   [Full Text] [Related]  

  • 8. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomitapide for the management of homozygous familial hypercholesterolemia.
    deGoma EM
    Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomitapide-a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia.
    Stefanutti C
    Curr Atheroscler Rep; 2020 Jun; 22(8):38. PubMed ID: 32557261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
    Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
    Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering treatment for homozygous familial hypercholesterolaemia.
    Santos RD
    Lancet; 2013 Apr; 381(9873):1182. PubMed ID: 23561997
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.
    Cuchel M; Bloedon LT; Szapary PO; Kolansky DM; Wolfe ML; Sarkis A; Millar JS; Ikewaki K; Siegelman ES; Gregg RE; Rader DJ
    N Engl J Med; 2007 Jan; 356(2):148-56. PubMed ID: 17215532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia.
    Raper A; Kolansky DM; Sachais BS; Meagher EA; Baer AL; Cuchel M
    J Clin Lipidol; 2015; 9(1):107-12. PubMed ID: 25670368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia.
    Davis KA; Miyares MA
    Am J Health Syst Pharm; 2014 Jun; 71(12):1001-8. PubMed ID: 24865757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsomal transfer protein inhibition in humans.
    Cuchel M; Rader DJ
    Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience.
    Sperlongano S; Gragnano F; Natale F; D'Erasmo L; Concilio C; Cesaro A; Golia E; Crisci M; Sperlongano R; Fimiani F; Russo M; Arca M; Limongelli G; Calabrò P
    J Cardiovasc Med (Hagerstown); 2018 Mar; 19(3):83-90. PubMed ID: 29389816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.